In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

被引：10
|
作者：
Rothstein, Sam N. [1 ]
Huber, Kelly D. [2 ]
Siuis-Cremer, Nicolas [2 ]
Little, Steven R. [1 ,3 ,4 ,5 ,6 ]
机构：
[1] Qrono Inc, Pittsburgh, PA USA
[2] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA
[3] Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA
[5] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA
[6] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 03期
关键词：
ERODING POLYMER MATRICES; PREDICTION; HIV-1; MODEL;
D O I：
10.1128/AAC.02440-13
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [41] In vivo evaluation of a new sustained-release formulation of morphine
    Araico, A.
    Saadeddin, A.
    Torres-Molina, F.
    Peris, J. E.
    PHARMAZIE, 2009, 64 (10): : 653 - 655
  • [42] CLINICAL EFFICACY AND BIOAVAILABILITY OF A SUSTAINED-RELEASE NIFEDIPINE FORMULATION
    PIOVELLA, C
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1987, 37-2 (07): : 832 - 835
  • [43] SUSTAINED-RELEASE CHARACTERISTICS OF A NEW IMPLANTABLE FORMULATION OF DISULFIRAM
    PHILLIPS, M
    GRESSER, JD
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (12) : 1718 - 1720
  • [44] SUSTAINED-RELEASE TABLET FORMULATION OF DIETHYLCARBAMAZINE .3.
    BAVEJA, SK
    RAO, KVR
    DEVI, KP
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 27 (2-3) : 157 - 162
  • [45] IMIPENEM CILASTATIN - EVOLUTION OF THE SUSTAINED-RELEASE INTRAMUSCULAR FORMULATION
    KAHAN, FM
    ROGERS, JD
    CHEMOTHERAPY, 1991, 37 : 21 - 25
  • [46] Preparation of Powdered Fish Oil as a Sustained-Release Formulation
    Aoki, Shigeta
    Nakagawa, Kiyotaka
    Hanzawa, Yasuhiko
    Matsumoto, Shunsuke
    Akutsu, Mitsuaki
    Kimizuka, Norihito
    Shimoyamada, Makoto
    Nishikawa, Masazumi
    Miyazawa, Teruo
    JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY-NIPPON SHOKUHIN KAGAKU KOGAKU KAISHI, 2014, 61 (10): : 467 - 474
  • [47] Formulation and Optimization of a Sustained-Release Tablet of Ketorolac Tromethamine
    Vatsaraj, Neha
    Zia, Hossein
    Needham, Thomas
    DRUG DELIVERY, 2002, 9 (03) : 153 - 159
  • [48] DEVELOPMENT AND PHARMACOKINETICS OF A NEW SUSTAINED-RELEASE FORMULATION OF DILTIAZEM
    THIERCELIN, JF
    NECCIARI, J
    CAPLAIN, H
    COURNOT, A
    COMBES, M
    DESMOLIN, H
    FLOUVAT, B
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 16 : S31 - S37
  • [49] INFLUENCE OF TECHNOLOGICAL FACTORS ON FORMULATION OF SUSTAINED-RELEASE TABLETS
    CAPAN, Y
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1989, 15 (6-7) : 927 - 956
  • [50] DEVELOPMENT OF A FORMULATION OF SUSTAINED-RELEASE POTASSIUM-CHLORIDE
    PEZOA, R
    JOPIA, O
    MONARDES, AM
    ARANCIBIA, A
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (13) : 1875 - 1882
12345